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Muscle-Directed Delivery of an AAV1 Vector
Leads to Capsid-Specific T Cell Exhaustion
in Nonhuman Primates and Humans
Gwladys Gernoux,1,2 Alisha M. Gruntman,1,2,3 Meghan Blackwood,1 Marina Zieger,1 Terence R. Flotte,1
and Christian Mueller1,2
1Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA; 2Department of Pediatrics, University of Massachusetts Medical School,
Worcester, MA, USA; 3Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, N. Grafton, MA, USA
With the US Food and Drug Administration (FDA) and Euro-
pean Medicines Agency (EMA) approvals for Zolgensma, Lux-
turna, and Glybera, recombinant adeno-associated viruses
(rAAVs) are considered efﬁcient tools for gene transfer. How-
ever, studies in animals and humans demonstrate that intra-
muscular (IM) AAV delivery can trigger immune responses
to AAV capsids and/or transgenes. IM delivery of rAAV1 in hu-
mans has also been described to induce tolerance to rAAV char-
acterized by the presence of capsid-speciﬁc regulatory T cells
(Tregs) in periphery. To understand mechanisms responsible
for tolerance and parameters involved, we tested 3 muscle-
directed administration routes in rhesus monkeys: IM delivery,
venous limb perfusion, and the intra-arterial push and dwell
method. These 3 methods were well tolerated and led to trans-
gene expression. Interestingly, gene transfer in muscle led to
Tregs and exhausted T cell inﬁltrates in situ at both day
21 and day 60 post-injection. In human samples, an in-depth
analysis of the functionality of these cells demonstrates that
capsid-speciﬁc exhausted T cells are detected after at least
5 years post-vector delivery and that the exhaustion can be
reversed by blocking the checkpoint pathway. Overall, our
study shows that persisting transgene expression after gene
transfer in muscle is mediated by Tregs and exhausted T cells.
INTRODUCTION
The adeno-associated virus (AAV) is a dependovirus belonging to the
parvovirus family. Its 4.7-kb genome carries 2 Rep and Cap genes
ﬂanked by 2 inverted terminal repeats (ITRs) and is packaged into
an icosahedral protein capsid composed of 3 proteins: VP1, VP2,
and VP3 at a 1:1:10 ratio. Despite its low encapsidation capacity, its
genetic simplicity and low immunogenicity have made it a promising
tool for gene transfer in the past decades. With the recent FDA and
EMA approvals for Zolgensma, Luxturna, and Glybera, recombinant
AAVs (rAAVs) are now, more than ever, considered efﬁcient and suc-
cessful viral vectors for the treatment of inherited disorders. Its variety
of serotypes offers a large spectrum of abilities to transduce tissues,
including the liver,1,2 muscle,3–6 central nervous system (CNS),7–9
and retina,10,11 as demonstrated in preclinical studies targeting
metabolic,12–16 neuromuscular,17–20 neurodegenerative,21,22 and
retinal23–25 disorders. Interestingly, certain serotypes of AAV capsids
elicit more robust immune responses than others, with AAV8 being
less immunoreactive and AAVrh32.33 being more immunoreactive
in mouse models.26,27 Furthermore, when protocols were translated
to patients, limits imposed by the host immune system have emerged.
Indeed, the study of T cell-mediated immune responses to AAV cap-
sids in patients have shown that, after gene transfer, memory T cells
can be reactivated and can lead to transduced cell clearance.28 The
ﬁrst evidence was an elevation of transaminases related to a cellular
immune response characterized by interferon (IFN)g-secreted
T cells in response to AAV capsid peptide libraries.28–30 Studies on
pre-existing immunity to AAV have shown that exposure to wild-
type AAV2 occurs early in life,31 suggesting that gene transfer past
3–18 years of age using AAV vectors can potentially result in the re-
activation of these memory T cell pools. Currently, one way to efﬁ-
ciently manage the cytotoxic immune response and restore gene
expression post-vector delivery is transient corticosteroid-based
immunosuppression.29,32
Elevation of serum enzymes is not always evidence of a deleterious im-
mune response resulting in loss of transgene expression. In a clinical
trial targeting the muscle in the absence of any immunosuppression,
Flotte et al.33 showed persistent alpha1-antitrypsin (AAT) protein
expression in serum, despite (1) an elevation of serum creatine kinase
and (2) the detection of IFNg-secreting cells to AAV1 capsid in periph-
eral bloodmononuclear cells (PBMCs). This was explained by the pres-
ence of muscle-inﬁltrated regulatory T cells (Tregs) 1 year post-vector
delivery in addition toAAV capsid persistence in situ.34 Tregs were also
detected in lipoprotein-lipase-deﬁcient (LPLD) patients35 after intra-
muscular (IM) gene transfer, suggesting that cellular immune response
to rAAV does not lead exclusively to cytotoxicity and gene transfer fail-
ure but can also result in immune tolerance. Altogether, these data
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highlight that (1) several factors can manage the nature of the T cell
response, including the AAV serotype, the dose, the administration
route, the transgene, and/or the promoter;36 and (2) the nature of the
tolerance mechanism and its kinetic are still not clearly established.
Here, we studied the mechanisms responsible for persisting transgene
expression after gene transfer in muscle in rhesus monkeys by
comparing three modes of delivery: IM; a high-volume venous limb
perfusion (VLP), also called hydrodynamic intravenous delivery;37,38
and an intra-arterial push and dwell (IAPD) method. To better charac-
terize the mechanisms involved, we focused on Tregs and exhausted
T cells. We performed an in situ immune cell analysis shortly after vec-
tor dosing (days 21 and 60) instead of analyzing peripheral immune re-
sponses. We showed that both Tregs and exhausted T cells might be
responsible for the absence of a cytotoxic immune response after IM
injection. Because we already had evidenced that IM injection may
induce an AAV-speciﬁc Treg response in humans at least 1 year
post-vector delivery, we focused on the functionality of exhausted
T cells in AAT-deﬁcient (AATD) patients. In the present study, we as-
sessed the functionality of these cells by blocking the PD1 pathway and
showed an increase of IFNg secretion when the checkpoint pathway is
blocked, demonstrating a capsid-speciﬁc T cell exhaustion.
Our results suggest that the absence of a deleterious T cell response to
the AAV capsid is mediated by Tregs and exhausted T cells and occurs
early after gene transfer to muscle and may offer a new way to interro-
gate in situ immune responses to the AAV capsid. Importantly, these
responses occurred in both humans and non-human primates without
either steroid therapy or any other form of immune modulation.
RESULTS
Experimental Design, Transgene Expression, and Cellular
Immune Response
Rhesus macaques were injected with a single-stranded (ss)AAV1-
CB-AAT vector at a dose of 6e12 viral genomes per kilogram (vg/
kg), corresponding to the highest dose injected in AATD patients
(ClinicalTrials.gov: NCT01054339).33 Three different methods of
delivery were tested: IM (n = 3), VLP (n = 3), and IAPD (n = 2)
(Table 1).39 As previously described by our group,39 the procedures
are well tolerated, and the vector biodistribution analysis showed a
broader distribution when the vector is delivered by VLP compared
to IM injection. To track protein expression and differentiate endog-
enous AAT from recombinant AAT, a c-Myc tag was added to the
recombinant rhesus AAT (rhAAT) sequence. The rhAAT-cMyc
fusion protein expression was measured at the mRNA level by
qRT-PCR and at the protein level in serum by a semiquantitative
immunoblot over time.39 Our results show that the protein expres-
sion was detected in all groups, with a higher protein expression
in the VLP group: up to an average of 90 mg/mL at 60 days post-in-
jection. The level of protein expression is respectively VLP > IM >
IAPD (Table 1).39 As expected, all the animals seroconverted after
rAAV administration, as illustrated by detection of anti-AAV1
neutralizing antibodies (NAbs) and immunoglobulin G (IgG) (Table
2). In contrast to results obtained in the phase II AATD clinical trial,
these animals showed sporadic and transient elevation in serum cre-
atine kinase or liver transaminases (alanine aminotransferase
[ALT]/aspartate aminotransferase [AST]). IFNg secretion was
measured by ELISpot on PBMCs prior to dosing and at necropsy.
Only one animal (RA0332, VLP group) showed a positive cellular
immune response to AAV1 capsid protein at day 60 post-injection
(Table 2),39 despite evidence of cell inﬁltrates in situ. Analysis of
cell inﬁltrates in the injected limbs reveals that IM vector injection
leads to a higher cell inﬁltration than the VLP and IAPD administra-
tion routes (Figure 1).
Activated Tregs Are Detected in Muscle after IM Injection in
Nonhuman Primates
To date, two studies have shown that AAV1 IM injection can lead to
Treg inﬁltration in injected muscles in AATD and LPLD patients.34,35
To verify that Tregs can be detected in injected or perfused muscles
post-AAV1 administration in non-human primates, muscle biopsies
were performed at day 21 post-vector administration, and muscles
were harvested at necropsy (day 60). After tissue dissociation, samples
were analyzed for the presence of regulatory T cells in situ. This anal-
ysis was performed by ﬂow cytometry. Regulatory T cells are deﬁned
as CD3+CD4+Helios+Foxp3+ cells (Figures 2A and S1A for isotype
controls), and activated Tregs are deﬁned as Tregs expressing
CD25. For each nonhuman primate, the injected or perfused muscle
and a contralateral muscle were analyzed at days 21 and 60 after
dosing (Figures 2B and 2C; Table S1). Our results show that all ani-
mals that were injected IM have inﬁltrated Tregs at day 21 (7%–
15% of CD4+ T cells), and these cells are still detected 60 days
post-dosing (7%–8% of CD4+ T cells) (Figures 2B and 2C; Table
S1). Some of the animals injected via VLP or the IAPD method had
inﬁltrated CD4+ T cells (Figure 2B), but none of these cells were Tregs
(Figure 2C). These results were then conﬁrmed by immunohisto-
chemistry. Since no Tregs were detected by ﬂow cytometry after
VLP and IAPD deliveries, we focused on muscle tissue from the IM
group (Figures 2D and S2A for negative control). Our data conﬁrm
that Tregs are present in the muscle and suggest that these cells
Table 1. Experimental Groups
Vector Route Dose Animal No.
Serum rhAAT-cMyc
Concentration at
Endpoint (mg/mL)
ssAAV1-CB-
rhAAT-cMyc
IM 6e12 vg/kg
RA1598 12
RA1683 50
RA0764 51
ssAAV1-CB-
rhAAT-cMyc
VLP 6e12 vg/kg
RA1567 92
RA0770 116
RA0332 61
ssAAV1-CB-
rhAAT-cMyc
IAPD 6e12 vg/kg
RA1562 20
RA1709 17
rhAAT, rhesus alpha1-antitrypsin; ss, single-stranded; CB, chicken b-actin promoter;
IM, intramuscular; VLP, venous limb perfusion; IAPD, intra-arterial push and dwell;
vg/kg, viral genomes per kilogram.
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play a role in maintaining transgene expression in situ after IM vector
administration in nonhuman primates.
Evidence of Exhausted T Cells in Injected Limb after Gene
Transfer in Muscle in Nonhuman Primates
Regulatory T cells are not the only mediator of immune regulation. As
we described in an AATD patient 1 year and 5 years after vector deliv-
ery,34,40 exhausted T cells can also be involved in AAV capsid tolerance.
As performed for the Tregs, we analyzed by ﬂow cytometry the muscle
tissues for the presence of exhausted T cells at day 21 and day 60 after
vector administration (Figure 3). Exhausted T cells are deﬁned as
CD3+CD8+PD1+ cells (Figures 3A and S1B for isotype controls)
and activated exhausted T cells are deﬁned as CD3+CD8+PD1+
CD69+ cells. For each nonhuman primate, the injected or perfused
muscle and a contralateral muscle were analyzed at both time points
(Figures 3B and 3C; Table S2). Our results show that all animals that
were injected IM have inﬁltrated exhausted T cells at day 21 (39%–
48% of CD8+ T cells), and these cells are still detected (47%–87% of
CD8+ T cells) (Figure 3C; Table S1) and express the CD69 activation
marker (Table S3) 60 days post-dosing. Some of the animals injected
by VLP or IAPD method have inﬁltrated CD8+ T cells expressing
the PD1 marker as well (Figures 3B and 3C). These results were then
conﬁrmed by immunohistochemistry, as illustrated in Figure 3D (Fig-
ure S2B for negative control). Altogether, our data suggest that T cell
exhaustion might also be involved inmaintaining transgene expression
after muscle-directed gene transfer.
Persistenceof AATExpression after GeneTransfer Is Drivenby T
Cell Exhaustion in AATD Patients
Our AATD clinical trial has shown that, despite an IFNg immune
response to AAV capsid, the transgene expression is maintained for
years after gene transfer, suggesting an unresponsiveness toward
the AAV capsid. Indeed, in situ analysis has shown that Tregs and
exhausted T cells are present up to 5 years post-dosing in injected
muscle.34,40 Because several studies have shown the reversal of the
exhaustion by in vitro blockade of these inhibitory pathways, we
have developed an assay to verify that functional exhausted T cells
are involved in persisting AAT expression in the patient still express-
ing the transgene 5 years post-vector administration. First, we
conﬁrmed by ELISpot that the PBMCs were still secreting IFNg in
response to AAV capsid peptides but also in response to AAV1 im-
munodominant peptides described by Hui et al.41 (Figure 4A; Table
S4). Then, PBMCs were restimulated in vitro for 48 h with the
AAV1 immunodominant peptides with or without PD1/PDL1 block-
ing antibodies or isotype controls. An IFNg-ELISpot assay was per-
formed and showed an increase in IFNg secretion when blocking
the PD1/PDL1 pathway (Figure 4B). The cell relative reactivity was
assessed and showed that the IFNg secretion increased by 44%
when the checkpoint pathway is blocked, compared to the reference
condition (stimulation with AAV1 peptides only; Figure 4C). Alto-
gether, these data suggest that the lack of a cytotoxic T cell response
to rAAV1 capsid is, indeed, mediated by exhausted T cells.
DISCUSSION
Despite the evidence of efﬁcacy of AAV vectors for the treatment of in-
herited diseases, some limitations imposed by the host immune system,
such as cellular immune responses to AAV vector and/or transgene,
persist. Depending on the administration route, the dose, and/or the
AAV serotype, gene transfer can result in a deleterious immune
response30,42–44 or tolerance.34,35 Because immune tolerance initiation
after AAV-based gene transfer inmuscle remains unknown, we studied
the mediators involved in persisting transgene expression after rAAV1
injection in muscle in rhesus monkeys by comparing three modes of
delivery (IM, VLP, and IAPD) and in an AATD patient who was in-
jected IM with an AAV1 vector . We showed that both Tregs and ex-
hausted T cells are detected early after muscle-directed gene transfer
and are involved in modulating immune response to AAV capsid in
nonhuman primates and humans.
Table 2. Humoral and Cellular Immune Responses to AAV Capsid
Route and
Animal No.
Anti-AAV1 IgG Concentration (mg/mL) Anti-AAV1 NAb Titer
IFNg Secretion to
rAAV1 CapsidPre-dose Day 21 Day 60 Pre-dose Day 21 Day 60
IM
RA1598 ND 18.2 76.4 <1:10 1:640 1:1,280 
RA1683 0.6 NA 1,080.2 1:10 1:1,280 1:20,480 
RA0764 ND 30.0 530.1 <1:10 1:1,280 1:10,240 
VLP
RA1567 ND 91.2 139.7 <1:10 1:2,560 1:5,120 
RA0770 ND 55.4 170.4 <1:10 1:1,280 1:5,120 
RA0332 ND 51.3 159.7 1:10 1:1,280 1:5,120 +
IAPD
RA1562 ND 19.8 120.4 <1:10 1:160 1:1,280 
RA1709 0.3 32.0 241.3 <1:10 1:320 1:1,280 
IM, intramuscular; VLP, venous limb perfusion; IAPD, intra-arterial push and dwell; NAb, neutralizing antibodies; ND, not detected, NA, not available; , no response; +, positive
response.
www.moleculartherapy.org
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In this study, we conﬁrmed in nonhuman primates that the injec-
tion of an AAV1 encoding for the AAT protein in muscle leads
to a sustained transgene expression for up to 60 days with no evi-
dence of an IFNg-positive response to the capsid. This is expected,
since a CD8 T cell-mediated cellular immune response to the capsid
had not been anticipated in preclinical models16,38,45 and had been
described for the ﬁrst time in hemophilia B patients treated with a
rAAV2.30 Although a capsid-speciﬁc immune response is not de-
tected in the periphery (PBMCs), we analyzed and characterized
the inﬂammation in situ. Our data conﬁrmed that the IM delivery
results in higher inﬂammation than VLP and IAPD deliveries.38,46
So far, IM delivery has been described as immunogenic with the in-
duction of antibodies to the transgene and loss of transgene expres-
sion. In this study, gene transfer in muscle leads to sustained trans-
gene expression explained by the presence of Tregs and exhausted
T cell inﬁltrates in situ. In our model, Tregs were detected only after
IM injection, whereas exhausted T cells were detected in animals
that were injected IM but also via VLP (2/3) and IAPD (1/2) deliv-
eries but only by ﬂow cytometry and at a lower frequency. These
ﬁndings in nonhuman primates led us to analyze the same cell pop-
ulation in humans after gene transfer in muscle. In AATD patients,
we have shown that, after 5 years post-vector delivery, Tregs and ex-
hausted T cells are still detected in muscle.40 Here, we focused on
exhausted T cell properties. These cells are usually found in chronic
diseases and are described to express PD1 receptor and to lose their
ability to secrete cytotoxic cytokines such as IFNg, interleukin-2
(IL-2), and tumor necrosis factor alpha (TNF-a).47 In the present
Figure 1. Detection of Cellular Infiltrates in the
InjectedMuscle or Perfused Limb after rAAV1 Dosing
Nonhuman primates were injected IM (n = 3), VLP (n = 3), or
IAPD (n = 2) with a ssAAV1 vector (6e12 vg/kg). Muscles
were harvested 60 days after dosing. Infiltrated cell pop-
ulations were analyzed by hematoxylin and eosin (H&E)
staining in a control monkey, quadriceps receiving an IM
injection (RA1683), VLP perfused quadriceps (RA0770),
and IAPD perfused quadriceps (RA1709). Each illustration
is representative of each group. Scale bars, 200 mm.
study, we show that AAV vectors can actually
induce T cell exhaustion in AATD patients
that can be reversed by immune checkpoint in-
hibitors. Altogether, our data suggest that both
Tregs and exhausted T cells are involved in
modulating the immune response to the AAV
capsid. More importantly, our results indicate
that these mechanisms seem to occur early after
gene transfer, as soon as day 21 post-dosing,
and last up to 5 years post-vector delivery.
Surprisingly, in our model, the absence of a detri-
mental immune response is observed when the
vector is injected in the muscle. In gene transfer
protocols, the liver has more often been described as a tolerogenic or-
gan, as illustrated in animal model.48–50 However, a systemic injection
has shown limits due to a capsid-speciﬁc cellular immune response
observed in high-dose patient groups injected with either rAAV2,28
rAAV8,29 or rAAV932 and was explained by the presentation of
AAV-capsid-derived antigen on major histocompatibility complex
class I (MHC I) expressed on hepatocytes.51 The fact that it was not
predicted in animal models can be due to the pre-existing immunity
to AAV capsid in humans.30,52,53 Even if monkeys are natural hosts of
AAV, their pre-existing capsid-speciﬁc T cells differ from those of hu-
mans, with an effector phenotype compared to a memory phenotype
in humans, and also have more restricted function: human T cells
produce mainly IFNg and IL-2 cytokines, while nonhuman primate
T cells produce mainly IL-2.54
In contrast to liver, where capsid clearance presumably occurs up to
16 weeks after gene transfer depending on vector serotype,55 in mus-
cle, the AAV vector seems to be trapped in muscle for years after IM
injection.34 This results in a potential persistent exposure of T cells
to capsid antigens that might be presented by antigen-presenting
cells mimicking a chronic disease and explaining the induction of
Tregs and exhausted T cells. Indeed, both cell types have shown
the ability to mediate tolerance in the case of chronic diseases due
to long duration of antigen exposure.56–59 The initiation of a regula-
tory response can also be explained by the requirement of a certain
concentration of epitopes to induce an active tolerance in opposition
to ignorance.60,61 In the case of a rAAV1 IM delivery, the vector stays
Molecular Therapy
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concentrated at the site of injection, as illustrated by the vector bio-
distribution data: the same dose is administered via IM, VLP, or
IAPD delivery, but the vector biodistribution is different, with a
less concentrated and more diffuse distribution in the injected
limb after VLP or IAPD delivery.37–39,62–64 Tregs can also mediate
T cell exhaustion,65 but this does not seem to be the case here.
Indeed, both cell types are detected early post-injection; more
importantly, exhausted T cells are detected after VLP and IAPD de-
livery, whereas Tregs are not.
In this study, we were able to correlate results obtained in monkeys to
those obtained with patients, but our data conﬁrm that monkeys do
not completely mimic the immune response to the AAV capsid
observed in humans. These observations highlight the complexity
Figure 2. Regulatory T Cells Infiltrate the Muscle after rAAV1 IM Injection
Nonhuman primates were injected IM, VLP, or IAPD with an ssAAV1 vector (6e12 vg/kg). Muscles were harvested 21 and 60 days after dosing and were dissociated as
described in the Materials and Methods section. Regulatory T cell population was analyzed by flow cytometry. (A) Gating strategy. RA1683, right quadriceps (injected
muscle), 60 days after dosing. T cells are gated as CD3+ cells in the lymphocyte subset, CD4 T cells are gated as CD3+ CD4+ cells in the CD3+ subset, and Tregs are gated as
Helios+Foxp3+ cells in the CD3+ CD4+ subset. (B and C) Percentage of CD4 T cells (B) and Tregs (C) in injected muscle or perfused limb (right quadriceps) at day 21 and day
60 after dosing. nd, not detected. (D) Detection of Tregs by immunohistochemistry in injectedmuscle after IM delivery (RA0764, day 60 post-injection). Scale bars, 10 mm. SS,
side scatter; FSC, forward scatter.
www.moleculartherapy.org
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of the human immune system that cannot be completely understood
with animal models, including those of nonhuman primates, which
differ in their immune repertoire and reactivity to AAV capsids.
Nevertheless, our study shows that, if analysis is performed in situ,
we may observe similarities between our two models.
In summary, we showed that AAV vector delivery in muscle mediates
T cell exhaustion and/or Treg response without preventing the forma-
tion of anti-AAV IgG or NAbs, which are critical for AAV readminis-
tration.66–68 Onemajor point to take into consideration is that these re-
sults were obtained when gene transfer is made in healthy muscles in
opposition to some previous preclinical and clinical trials where the
IM delivery was used to treat neuromuscular disorders, such as
Duchenne muscular dystrophy (DMD)42 or limb-girdle muscular dys-
trophy type 2D (LGM2D).69 In these models, the immunogenicity of
the IM route might be enhanced because of the inﬂammatory environ-
ment caused by the disease itself.70,71 A good alternative to the IM de-
livery would be the VLP route, which still leads to T cell exhaustion and
Figure 3. Exhausted T Cells Infiltrate the Muscle after rAAV1 Administration
Nonhuman primates were injected IM, VLP, or IAPD with an ssAAV1 vector (6e12 vg/kg). Muscles were harvested 21 and 60 days after dosing and were dissociated as
described in Materials and Methods. The exhausted T cell population was analyzed by flow cytometry. (A) Gating strategy. RA1683, right quadriceps (injected muscle),
60 days after dosing. T cells are gated as CD3+ cells in the lymphocyte subset, CD8 T cells are gated as CD3+ CD8+ cells in the CD3+ subset, and exhausted T cells are gated
as PD-1+ cells in the CD3+ CD8+ subset. (B and C) Percentages of CD8 T cells (B) and exhausted T cells (C) in injected muscle or perfused limb at day 21 and day 60 after
dosing. nd, not detected. (D) Detection of exhausted T cells by immunohistochemistry in injectedmuscle after IM delivery (RA0764, day 60 post-injection). Scale bars: 10 mm.
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provides higher transgene expression. Other alternatives can also be
explored, such as modulating the dose or using less prevalent72–74 or
less immunogenic27,75 AAV serotypes or even capsid-modiﬁed
rAAV.76 Indeed, the transduction efﬁciency of dendritic cells (DCs)
depends on AAV serotype and/or genome conformation (ss versus
self-complementary)27,77–79 and might explain why some serotypes
are more immunogenic or, conversely, more tolerogenic than others.
In the case of capsid-engineered vectors, we can imagine that the capsid
circumvents natural pre-existing immunity. Actually, in recent preclin-
ical and clinical trials using engineered capsids, the immune response
does not occur as frequently as in previous trials.80
In conclusion, our data show that rAAV gene transfer may result in
the absence of a deleterious T cell response to the capsid, and at least
two cell populations are involved: Tregs and exhausted T cells. These
ﬁndings, in addition to the characterization of immune responses in
seronegative and seropositive patients,53 will help in developing safer
gene transfer protocols and the establishment of new immune modu-
latory strategies.
MATERIALS AND METHODS
Vector Production
Nonhuman Primate Study
Vector design and manufacturing has been previously described by
Gruntman et al.39 Brieﬂy, the CB-rhAAT-cMyc expression cassette
has been packaged into an ssAAV1 capsid using the herpes simplex
virus 1 (rHSV1) system, concentrated by tangential ﬂow, exchanged
to Ringer’s buffer, and ﬁltered through a 0.2-mm ﬁlter. The vector
was manufactured by Applied Genetic Technologies(AGTC).
AATD Phase II Clinical Trial
The rAAV1-CB-hAAT vector used in the AATD clinical trial has
been previously described.33,81 Brieﬂy, the rAAV1-CB-hAAT vector
has been made using the rHSV1 system and puriﬁed by chromatog-
raphy followed by AVB Sepharose afﬁnity chromatography.
Study Design
Nonhuman Primate Study
Rhesus monkeys with a NAb titer to AAV1 at or below 1:10 were
selected. The NAb titer was determined by the University of
Massachusetts Gene Therapy Vector Core using an in vitro assay.
At study day 0, three groups of animals were injected with 6e12
vg/kg of an ssAAV1-CB-rhAAT-cMyc by IM (n = 3), VLP (n = 3),
or IAPD (n = 2) delivery. At study day 21, blood was drawn,
and muscle biopsies were collected. At study day 60, animals were
euthanized; blood and tissues were collected for evaluation. All the
animal work was done under the approval and supervision of the
Lovelace Respiratory Research Institute Animal Care and Use
Committee.
The injection procedures are detailed by Gruntman et al.39 Brieﬂy, the
IM injection procedure consisted of four 0.5-mL injections in each
quadriceps and gastrocnemius muscles in the right hindlimb.
The VLP animals received a volume of 50 mL/kg of the rAAV1 vector
diluted in Lactated Ringer’s solution (LRS). An intravenous catheter
was placed into the saphenous vein of the right pelvic limb. Then, a
tourniquet was placed around the level of the proximal thigh. The
vector was infused over 5–10 min. After infusion, the tourniquet re-
mained tight for 15 min and then was released.
Figure 4. PD1/PDL1 Blocking Leads to Exhaustion Reversal in Patient PBMCs
PBMCs were isolated 5 years post-injection. (A) PBMCs were stimulated in vitro with overlapping peptides (15-mers overlapping by 10 aa) spanning the VP1 capsid protein
sequence or AAV1 immunodominant peptides. (B) PBMCs were stimulated in vitro with AAV1 immunodominant peptides for 48 h in the presence or absence of PD1/PDL1
antibodies or isotype controls. For each experiment in (A) and (B), the negative control consisted of unstimulated cells (medium), whereas CD3/CD28 stimulation was used as
a positive control for cytokine secretion. Responses were considered positive when the number of spot-forming units (SFUs) per 1e6 cells was >50 and at least 3-fold higher
than in the control condition (dotted line); asterisks denote positive response. (C) IFNg secretion fold change expressed as percent reactivity relative to the AAV1 peptide
stimulation condition. Each condition was performed in triplicate. Error bars represent SEM.
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Animals in the IAPD group received a volume of 12.5 mL/kg rAAV1
vector diluted in LRS. An incision was made in the lower anterior
thigh of the right pelvic limb, and the superﬁcial femoral artery and
vein were dissected and isolated with silk suture. Arterial and venous
access was obtained with sheath catheters. The arterial and venous
balloon catheters were then placed through their respective sheathes.
After a pre-ﬂush with LRS (5 mL/kg), the ssAAV1-CB-rhAAT-cMyc
vector was infused in a volume of 12.5 mL/kg through the arterial
catheter sheath port. After infusion, the vector solution was allowed
to dwell for 15 min. Then, a post-ﬂush of 5 mL/kg LRS was injected
into the arterial catheter. After the infusion had been completed, the
balloons were deﬂated, and the catheters were removed.
AATD Phase II Clinical Trial
The study design was previously reported by Flotte et al.33 This
study is registered with ClinicalTrials.gov (ClinicalTrials.gov:
NCT01054339) and was conducted under an IND (investigational
new drug) with the approval of the University of Massachusetts Med-
ical School and Cincinnati Children’s Hospital institutional review
boards and institutional biosafety committees and in accordance
with the tenets of the Declaration of Helsinki. This study was con-
ducted as an open-label, non-randomized, multicenter, sequential,
3-arm, phase II clinical trial to determine the safety and efﬁcacy of
IM administration of a rAAV1-CB-hAAT vector. Nine subjects (three
per cohort) received IM doses of rAAV1-CB-hAAT (6e11, 1.9e12, or
6e12 vg/kg body weight). For the present study, blood was collected
on subject 308 (high-dose cohort) at 5 years post-dosing.
NAb Assay
Sera sampled prior to dosing, day 21, and at necropsy were heat inac-
tivated for 30 min at 56C. AAV1-CMV-LacZ (109 gc/well) was incu-
bated with 2-fold serial dilutions of samples for 1 h at 37C, 5% CO2.
The mixture was added to Huh7 cells (1e5 cells) previously infected
with an adenovirus (100 particles per well) and incubated for 18–
22 h at 37C, 5% CO2. Cells were washed and developed with the Gal-
acto-Star Kit (Applied Biosystems). Luminescence was measured
with a luminometer. The NAb titers are expressed as the highest dilu-
tion that inhibited b-galactosidase expression by at least 50%
compared to a negative mouse serum control.
Anti-AAV1 IgG ELISA
Anti-AAV1 IgG antibodies were detected by enzyme-linked immu-
nosorbent assay (ELISA). Plates were coated with 5e9 vg of rAAV1
vector in coating buffer (carbonate-bicarbonate, 0.5 M [pH = 9.6])
at 4C overnight. The plates were blocked with PBS-Tween 0.1%
for 1 h at 37C. Monkey sera were serially diluted and incubated
for 2 h at 37C. Plates were then incubated with an anti-human
IgG horseradish peroxidase (HRP) antibody (A80-104P, Bethyl Lab-
oratories) for 1 h at room temperature (RT). Substrate (tetramethyl-
benzidine [TMB]; BD Biosciences) was added, and plates were incu-
bated for 7 min at RT. The reaction was stopped using 2 N H2SO4.
Plates were read in a spectrometer (VersaMax, Molecular Devices)
at 450 nm.
H&E Staining
Skeletal muscle parafﬁn sections (8 mm)were collected on slides. H&E
staining was performed as per standard histological protocols using
formolin-ﬁxed and parafﬁn-embedded muscle sections. The slides
were observed using a Leica DM5500B microscope.
Muscle Dissociation
Muscle biopsies and muscles were harvested 21 and 60 days after
AAV vector injection. Tissues were cut into approximately 5-mm3
pieces and incubated in RPMI media supplemented with DNase
I (62.5 U/mL; Zymo Research) and collagenase (0.25 mg/mL; Roche)
for 2 h at 37C. Cell suspension was homogenized and ﬁltered using a
70-mm cell strainer before staining for ﬂow cytometry analysis.
Flow Cytometry
Regulatory T cells and exhausted CD8+ T cell populations were
analyzed using CD3/CD4/Helios/FoxP3/CD25 and CD3/CD8/PD1/
CD69markers, respectively. Extracellular staining consisted of cell in-
cubation on ice for 30 min. Cells were then washed twice with 1 PBS
and re-suspended in 1 PBS supplemented with 0.5% fetal bovine
serum (FBS) and 2 mM EDTA. FoxP3 staining and Helios intracel-
lular staining were performed according to the manufacturer’s rec-
ommendations (anti-human FoxP3 Flow Kit, BioLegend). Cells
were acquired using a BD FACS LSRII ﬂow cytometer (BD Biosci-
ences) and analyzed with FlowJo software (v.10.1; Tree Star).
Immunohistochemistry
Skeletal muscle cryosections (5 mm) were collected on slides, air dried,
and ﬁxed with 3% paraformaldehyde (PFA) (Thermo Scientiﬁc) for
3 min. Saturation was performed in 10% goat serum (S-1000, Vector
Laboratories) and 5% BSA (BP1600-100, Thermo Scientiﬁc) for
45 min at RT. Then, sections were incubated in blocking buffer anti-
bodies overnight at 4C. Polyclonal rabbit anti-human CD3 (1:100)
(A0452, Dako), monoclonal mouse anti-human CD4 human
(1:100) (317402, BioLegend), monoclonal rat anti-human CD8
(1:100) (MCA351GT, Bio-Rad), monoclonal mouse anti-human
FoxP3 (1:100) (14-4777-82, Invitrogen), and monoclonal mouse
anti-human PD1 (1:100) (329902, BioLegend) antibodies were used
to detect Tregs (CD3+CD4+FoxP3+) and exhausted T cells (CD3+-
CD8+PD1+). After washing with PBS, sections were incubated with
goat anti-rabbit Alexa Fluor 555-conjugated antibody (1:500)
(A32732, Invitrogen) combined with goat anti-mouse (A21242, Invi-
trogen) or goat anti-rat (1:500) (A21247, Invitrogen) Alexa Fluor 647-
conjugated antibodies or with goat anti-mouse Alexa Fluor 488-con-
jugated antibody (1:500) (A21121, Invitrogen) for 1 h at RT. Nuclei
were counterstained with DAPI for 5 min at RT (0.001 mg/mL)
(10236276001, Sigma Aldrich). Finally, slides were mounted with
Clear-Mount (17985-12, Electron Microscopy Sciences). Images
were captured using a Leica DM5500B microscope and Leica Appli-
cation Suite AF v.3.1.0 build 8587 imaging software.
IFNg ELISpot Assay
PBMCs were isolated 5 years post-injection, and the IFNg ELISpot
assay was performed according to the manufacturer’s
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recommendations (Human IFN-g ELISpotBASIC, MABTech). Brieﬂy,
PBMCs were stimulated in vitro for 48 h with overlapping peptides
spanning the AAV1 capsid VP1 sequences and divided into 3 pools
(2 mg/mL, 15-mers overlapping by 10 aa, Mimotopes, Mulgrave,
VIC, Australia) or stimulated with the AAV1 immunodominant pep-
tides (5mg/ml, Mimotopes, Mulgrave, VIC, Australia; Table S4). A
negative control consisted of unstimulated cells (medium only),
whereas CEFT (JPT Peptide Technologies, Berlin, Germany) and
CD3/CD28 stimulation were used as a positive control for cytokine
secretion. Spot number was determined using an iSpot ELISpot
Reader ELR068IFL (AID) and analyzed with AID ELISpot Reader
software v.6.0. Responses were considered positive when the number
of spot-forming units (SFUs) per 1e6 cells were >50 and at least 3-fold
higher than in the control condition.
PD1/PDL1 Blocking Assay
The PD1/PDL1 assay was conducted as described in the previous
IFNg ELISpot Assay section, except that PBMCs were stimulated
in vitro for 48 h with the AAV1 immunodominant peptides (5 mg/
mL, Mimotopes, Mulgrave, VIC, Australia; Table S4) with either no
antibodies or 1 mL/100 mL cells of PD1/PDL1 antibodies (BioLegend)
or their respective isotypes (BioLegend).
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